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Objective: Takotsubo cardiomyopathy is a heart syndrome with an acute onset defined 
by chest symptoms, ST segment elevation on electrocardiograms. Patients with 
Takotsubo cardiomyopathy are sometimes misdiagnosed as having acute myocardial 
infarction (AMI). Therefore non-invasive diagnostic method needed to be established 
for setting up appropriate strategies. The purpose of this study was to detect myocardial 
metabolic abnormalities and to determine the diagnostic usefulness of 
123
I-BMIPP 
imaging in patients with Takotsubo cardiomyopathy. Methods and results: We 
examined 16 patients with Takotsubo cardiomyopathy and 12 with AMI in the left 
anterior descending artery lesion. All patients were studied with resting 
123
I-BMIPP 
imaging. Total defect score (TDS) of 
123
I-BMIPP and perfusion were 
semi-quantitatively determined with SPECT imaging using a 17-segment 5-point model. 
TDS of 123I-BMIPP were 4.8±2.7 in patients with Takotsubo cardiomyopathy and 
22.4±10.7 in AMI. The ratio of summed BMIPP defect score of non-apical to apical 
segments in Takotsubo cardiomyopathy was smaller than that of the patients with AMI 
(0.1±0.1 vs. 1.1±0.7, p<0.0001), indicating 123I-BMIPP abnormalities were exclusively 
observed in apical area. The ratio of summed perfusion defect scores of non-apical to 
apical segments in Takotsubo cardiomyopathy did not differ significantly from that of 
AMI (0.52±0.6 vs. 0.57±0.3, p=NS). Summed BMIPP defect score in apical area of 
Takotsubo cardiomyopathy was larger than that of perfusion defect score (3.9±2.7 vs. 
1.8±1.8, p=0.04). Conclusion: Impaired metabolic metabolism exclusively in apical 
region was observed by 
123
I-BMIPP SPECT images in Takotsubo cardiomyopathy. 
These typical metabolic SPECT features of the disease can be utilized on differential 
diagnosis of Takotsubo cardiomyopathy.  
 2 
Introduction 
Recent reports have described a reversible left ventricular dysfunction with 
symptoms similar to those of acute myocardial infarction but without coronary artery 
lesions even during the acute phase with ST segment elevation [1-2]. This dysfunction, 
known as ‘Takotsubo cardiomyopathy’ (transient left ventricular apical ballooning), 
characteristically resolves within a few weeks [3-4]. The Japanese word “Takotsubo” 
means an octopus fishing pot with a round bottom and a narrow neck. Patients with 
Takotsubo cardiomyopathy are sometimes misdiagnosed as having acute myocardial 
infarction (AMI) of left anterior descending (LAD) coronary artery [5-7]. Coronary 
angiography is conducted to exclude coronary artery disease [8]. Noninvasive 
diagnostic method is needed to set up appropriate strategies in patients with Takotsubo 
cardiomyopathy. Furthermore its origin and detailed clinical features of this disease 
remain unknown [9].  
Myocardial fatty acid metabolic imaging with 123I-beta-methy-iodophenyl 
pentadecanoic acid (BMIPP) has been used for the evaluation of various cardiac 
diseases such as ischemic heart disease [10-11], dilated or hypertrophic 
cardiomyopathies [12]. Several reports showed that 123I-BMIPP was superior to 
perfusion imaging for detecting myocardial damage of patients with ischemic heart 
disease or cardiomyopathy [12-13]. However, few studies have reported in detail on the 
diagnosis and the metabolism in Takotsubo cardiomyopathy in comparison with AMI 
[14-15].  
We analyzed clinical and radionuclide imaging data, including metabolic 
imaging in patients with Takotsubo cardiomyopathy in an attempt to detect myocardial 
metabolic abnormalities and to determine the diagnostic usefulness of 
123
I-BMIPP 




 The subjects included 16 patients with Takotsubo cardiomyopathy and 12 patients 
with AMI of LAD. All patients admitted to our hospital and underwent 
123
I-BMIPP 
scintigraphy during hospitalization. Study subjects had Takotsubo-like left ventricular 
dysfunction, and were hospitalized at our university hospital. All patients were clinically 
diagnosed with Takotsubo-like left ventricular (LV) dysfunction according to the 
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following criteria: (1) LV wall motion abnormality mainly at the apex, (2) sudden 
occurrence of heart failure. (3) absence of coronary artery disease on coronary 
angiography, (4) complete normalization of the LV dysfunction within a few weeks [13]. 
For comparison, the subjects include the patients with AMI who admitted to hospital 
with a diagnosis of the first anterior AMI. Each patient successfully underwent 
percutaneous coronary intervention and obtained good coronary flow. All of the patients 
had culprit lesions in the proximal LAD, and only patients with single-vessel were 
enrolled in this study. 
 The study was summarized retrospectively and was approved by our institutional 
ethics committee.  
 
123
I-BMIPP Imaging  
 123I-BMIPP at a dose of 111 MBq was injected slowly through the antecubital vein 
at rest after a 3-hour fast.  The SPECT data was obtained approximately 20 minutes 
after injection. A wide field-of-view dual-head detector camera (Symbia T6, Siemens Co. 
Tokyo, Japan) equipped with a low-medium-energy, general-purpose collimator without 
X-ray-based attenuation correction [16]. Thirty-two images were obtained for 40 
seconds in each 6˚ interval.  Image reconstruction was performed with a nuclear 
medicine computer system (Siemens Co. Tokyo, Japan) by means of a filtered 
back-projection algorithm without attenuation correction. Short-axis, the vertical 
long-axis, and the horizontal long-axis slices, each 6 mm thick were reconstructed.  
 
Myocardial perfusion Imaging 
  Myocardial perfusion study was performed at rest using 740MBq 
of 99mTc-labelled sestamibi or tetrofosmin. Electrocardiography-gated SPECT images 
were acquired with a 64x64 matrix, 6˚ step and 360˚ rotation.  
 
Data Analysis: 
 Segmental uptake of 
123
I-BMIPP was quantified using semi-quantitative scores by 
QPS software (Cedars Sinai Medical Center, LA, USA) and was confirmed by two 
experienced nuclear cardiologists. A 17-segment model of left ventricle was used with a 
5-point scale (0= normal uptake, 1 = mildly-reduced uptake, 2 = moderately-reduced 
uptake, 3 = severely-reduced uptake and 4 = no uptake) (Figure1). The sum of 17 
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segments was defined as total defect score (TDS). BMIPP TDS were calculated by 
adding the scores of 17 segments on the 
123
I-BMIPP rest images, reflecting the severity 
of impaired fatty acid metabolism. The perfusion TDS was similarly calculated for 
perfusion studies, reflecting the severity of impaired myocardial perfusion. Apical 
summed defect score was defined as summed score of segments 13-17, and non-apical 
summed defect score as summed score of segments 1-12.  A mismatch score between 
perfusion and 
123
I-BMIPP was calculated by subtracting perfusion TDS from BMIPP 
TDS. A mismatch between perfusion and BMIPP was defined to exist when mismatch 
score is 2 or more. 
 
Statistical analysis  
 All values are presented as mean values ± standard deviation. To examine 
differences between groups, t-test and non-parametric analysis as 
Wilcoxon/Kruskal-Wallis test were used to compare the two data and p values of less 




Table 1 shows the clinical characteristics of the study subjects with Takotsubo 
cardiomyopathy and AMI. Clinical features on admission in patients with Takotsubo 
cardiomyopathy were as follows. In a group of 16 patients with Takotsubo 
cardiomyopathy, 8 were men and the mean age of the group was 72±3 years, ranged in 
age from 55 to 85 years old. In 12 patients with AMI, 8 were men and the mean age was 
67±3 years, ranged from 44 to 91 years old. Plasma levels of peak creatinine 
phosphokinase on admission in patients with Takotsubo cardiomyopathy were 261±337 
IU/L, and 2116±1861 IU/L in AMI. The BMIPP studies were performed 11.1±2.1 days 
from admission in patients with Takotsubo cardiomyopathy and 14.6±2.5 days in 
patients with AMI.  
 
123
I-BMIPP SPECT images  
BMIPP TDS in patients with Takotsubo cardiomyopathy was 4.8±2.7, and 
22.4±10.7 in AMI. 123I-BMIPP defect score of the 17 segments of left ventricle in 
patients with Takotsubo cardiomyopathy and AMI are shown in Table 2. 
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Figure 2 depicts polar map of BMIPP and perfusion imaging, and coronary 
angiogram in a case of a 66 year-old male patient with Takotsubo cardiomyopathy.  
Apical summed defect score were 3.9±2.7 in Takotsubo cardiomyopathy, and 
10.8±5 in AMI (Table 2). Non-apical summed defect scores were 1.1±2.1 in Takotsubo 
cardiomyopathy, and 11.7±7.1 in AMI. BMIPP summed defect score of apical and 
non-apical segments were compared and the ratio of BMIPP non-apical segment to 
apical segment was calculated. The ratio of apical and non-apical summed BMIPP 
defect score of Takotsubo cardiomyopathy was smaller than that of the patients with 
AMI (0.1±0.1 vs. 1.0±0.1, p<0.0001) (Figure 3). 123I-BMIPP showed reduced uptake 
exclusively in the apical segments of the myocardium, indicating impairment of 
metabolic abnormalities in patients with Takotsubo cardiomyopathy. 
 
99mTc perfusion images 
99mTc perfusion SPECT imaging was performed in 13 out of 16 subjects with 
Takotsubo cardiomyopathy and all 12 patients with AMI. The interval between two 
studies was 3.7 ±3.7 days and 3.2 ±2.3 days in patients with Takotsubo cardiomyopathy, 
and AMI, respectively. The perfusion TDS in patients with Takotsubo cardiomyopathy 
was significantly lower than in those with AMI (2.6±2.9 vs. 13.3±9.2, p<0.0001). No 
significant difference was observed in perfusion summed defect score between apical 
area and non-apical area in Takotsubo cardiomyopathy (1.8±1.8 vs. 0.9±1.4, p=NS) and 
in AMI (8.7±5.2 vs. 4.7±4.5, p=NS). The ratio of summed perfusion defect scores of 
apical and non-apical segment scores of Takotsubo cardiomyopathy did not differ 
significantly from that of AMI (0.52±0.6 vs. 0.57±0.3, p=NS) (Figure 4).  
Comparison of perfusion SPECT data between Takotsubo cardiomyopathy 
and AMI in 17 segments of left ventricle is shown in Table 3. BMIPP defect score in 
apical area of Takotsubo cardiomyopathy was larger than that of perfusion defect score 
(3.9±2.7 vs. 1.8±1.8, p=0.04). The mismatch between perfusion and 123I-BMIPP was 
larger in patients with AMI than in those with Takotsubo cardiomyopathy (9.1±7.5 vs. 
2.7±1.5 in patients who underwent both BMIPP and perfusion, p=0.006). Figure 4 
shows the location of the mismatched area between BMIPP and perfusion scan in 
patients with Takotsubo cardiomyopathy and AMI in 17 segments of left ventricle. Six 
mismatched areas (123I-BMIPP defect larger than perfusion defect) were observed in 
patients with Takotsubo cardiomyopathy and 50 mismatched areas in AMI. In patients 
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with Takotsubo cardiomyopathy, mismatch between perfusion and 123I-BMIPP were 
observed exclusively in the apical lesion, including apical lateral, apical inferior and 
apex. In patients with AMI, a mismatch in the apical segment was observed in 12 out of 




Our study shows the characteristics of regional pattern of metabolic 
abnormalities in patients with Takotsubo cardiomyopathy differs from that of acute 
myocardial infarction. Metabolic abnormalities in Takotsubo cardiomyopathy are found 
exclusively in the apical portion, which is clearly different from the defects on 
myocardial perfusion scan. Such information of cardiac metabolic 123I-BMIPP imaging 
can be used to detect myocardial injury and be used as an important tool to diagnose the 
disease. 
Previous reports described that Takotsubo cardiomyopathy resembles an acute 
myocardial infarction [17-19]. About 1% of all suspected AMI were diagnosed as 
Takotsubo cardiomyopathy [2, 14]. Since electrocardiographic abnormalities resemble 
AMI, the patients with Takotsubo cardiomyopathy are sometimes misdiagnosed. 
Therefore the diagnosis of Takotsubo cardiomyopathy continues to be a challenge, and 
evaluation of the severity of the disease by metabolic imaging has not been fully 
established.  
 
Fatty acid metabolism and Ischemic Heart Disease    
 Ischemia may cause a reduction of fatty acid utilization and shift from fatty 
acid to glucose utilization in the myocardium. 123I-BMIPP is metabolized in the 
myocardium and its metabolism is closely related to myocardial carbohydrate utilization. 
Therefore we assumed that the metabolic abnormalities were detected on the cellular 
level or as a microcirculation abnormality on 
123
I-BMIPP imaging. In ischemic heart 
disease Tamaki et al. first described that discordant 
123
I-BMIPP uptake less than 
thallium uptake in 17 of 28 patients with myocardial infarction [10]. Such 
discordant 
123
I-BMIPP uptake was observed more often in areas of acute than chronic 
myocardial infarction (59% at <4 weeks versus 31% at >4weeks after onset), and more 
often in areas supplied by revascularized arteries than in areas supplied by 
non-revascularized arteries (74% versus 28%). Recent study showed that the 
perfusion-metabolism information could improve the risk stratification of the patients 
with coronary artery disease [20]. 
 One of the major applications of 
123
I-BMIPP SPECT is to the diagnosis of 
acute coronary syndrome in the use of emergency department practice. The imaging 
could add incremental diagnostic value to the initial clinical information. Kawai et al. 
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reported a sensitivity of 
123
I-BMIPP imaging of 74% to detect obstructive coronary 
stenosis or provocative spasm, when it was performed within 3 days of symptoms [21]. 
In addition cardiac metabolic abnormalities were seen in many patients with coronary 
spasm, and the imaging could be used to monitor the response to treatment [22]. These 
findings were confirmed by multicenter study in United State [23]. This noninvasive 
scintigraphic method is widely applied to diagnosing acute coronary syndrome and 
might represent the most suitable approach to investigate cardiac metabolism especially 
in the early period on admission without any risk of the examination itself. These 
microvascular circulation abnormalities could be detected by metabolic 
123
I-BMIPP 
imaging in the resting state. Reduced coronary flow is sometimes observed after 
emergency angiography without coronary stenosis, which is termed as no-reflow 
phenomenon. Therefore coronary spasm including epicardial coronary artery and 
coronary micro-vessels cannot be ruled out as one of the mechanism of causing 
myocardial ischemia [24]. Less 
123
I-BMIPP uptake than perfusion is called “mismatched 
myocardium”, which indicates the presence of ischemic and jeopardized myocardium 
[25]. The combined imaging with 
123
I-BMIPP and perfusion may be used to identify 
high-risk subjects among patients with chest pain syndrome [21]. 
 
Fatty acid metabolism in Takotsubo cardiomyopathy 
 
123
I-BMIPP in this study of patients with Takotsubo cardiomyopathy showed 
reduced uptake in the apical segment of the myocardium, indicating impairment of fatty 
acid metabolism in non-infarcted myocardium. Our study showed mismatched area in 
sub-acute phase in Takotsubo cardiomyopathy in accordance with previous reports [13, 
14]. The mismatch may indicate jeopardized but viable myocardium, reflecting transient 
ischemic damage or metabolically stunned myocardium. The area of metabolic 
abnormality in the apical segment was relatively smaller than that of AMI in LAD 
lesion. There are few reports on the fatty acid metabolism of Takotsubo cardiomyopathy. 
Kuritsu et al. reported that time course of myocardial perfusion and fatty acid 
metabolism in patients with Takotsubo-like left ventricular dysfunction [13, 14]. 
Mismatched area observed in the acute phase of the disease, was similar finding to 
stunned myocardium. Ito et al. reported myocardial metabolic abnormality combined 
with other nuclear tracers, which resembled with that of AMI, suggesting stunned 
myocardium or impaired microcirculation as a causative mechanism of Takotsubo 
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cardiomyopathy [13]. Regional semi-quantitative analysis in this study reveals that the 
cardiac metabolic abnormalities detected by 123I-BMIPP imaging are only in the apical 
area, which is one of the typical metabolic SPECT features of Takotsubo 
cardiomyopathy.  
 Although the pathogenesis of Takotsubo cardiomyopathy is undetermined, 
multivessel spasm, coronary microvascular dysfunction or catecholamine toxicity after a 
severe emotional trigger, surgical or medical procedure has been proposed to explain the 
provocative pathophysiology of Takotsubo cardiomyopathy [26-29]. Recent studies 
reported that coronary spasm was observed in about 28.6% of the patients with 
Takotsubo cardiomyopathy [30]. Increased sympathetic tone from mental stress possibly 
causes microvascular spasm, and induce coagulation, formation and dissolution of fibrin. 
Recurrence occurs in about 11.4% of patients with Takotsubo cardiomyopathy during 
4-year observation with no evidence of coronary progression [31]. Apical metabolic 
abnormalities may in part be explained by a metabolic disorder in the myocardium 
subsequent to a catecholamine surge or microvascular spasm. With hypothesis of 
metabolic stunned myocardium as a causative mechanism of Takotsubo cardiomyopathy, 
BMIPP imaging seems to be one of the most specific diagnostic techniques.  
 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) study 
on glucose-loaded method can measure glucose utilization in the myocardium. 
Recent 18F-FDG-PET study showed reduced apical uptake in patients with Takotsubo 
cardiomyopathy, which is similar result of the patients with myocardial infarction 
[32-34]. The studies suggested that the glucose metabolism was suppressed especially in 
apical segment of stunned myocardium, suggesting preserved oxygen metabolism [35]. 
  
Diagnostic value of 
123
I-BMIPP SPECT  
We assume that the present study provides us a clue to differentiate diagnosis 
in the early time of admission between Takotsubo cardiomyopathy and acute coronary 
syndrome, since Takotsubo cardiomyopathy could be recognized by the characteristics 
of metabolic abnormalities associated with ischemic memory. Previous reports 
suggested that abnormalities in resting perfusion imaging in sub-acute phase were not 
obvious [36]. Our study showed the metabolic abnormality was larger than that of 
perfusion. Therefore metabolic imaging with 
123
I-BMIPP would be a better indicator of 
myocardial damage than perfusion study. Stress myocardial perfusion scintigraphy with 
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exercise and/or vasodilatory drugs may help diagnose and stratify risk in patients with 
chest pain. However stress test is not suitable or recommend for the patients with chest 
pain and unstable angina. The addition of 
123
I-BMIPP imaging information to the initial 
available clinical data provides incremental value for the early diagnosis of Takotsubo 
cardiomyopathy, potentially allowing determination of the presence or absence of 
Takotsubo cardiomyopathy to be made much earlier in the evaluation process 
[37]. 
123
I-BMIPP imaging might be able to predict therapeutic effects and set up 
appropriate strategies in patients with suspected acute coronary syndrome or Takotsubo 
cardiomyopathy. 
 
Limitation of our study  
The present study had several limitations. First this was a single-center 
retrospective observational study. Second, small number of patients investigated 
requires further intensive studies to confirm its usefulness in determining the prognosis 
in Takotsubo cardiomyopathy. Third, the different days of BMIPP acquisition from the 
admission between Takotsubo cardiomyopathy and AMI may affect the size of 
mismatched area. Fourth, we did not perform repeated 
123
I-BMIPP study. Although 
beta-blocker and calcium channel blocker may prevent stress-induced cardiac 
dysfunction [38, 39], a usefulness to assess the response to therapy needs to be 




Metabolic abnormality exclusively in the apical region was observed in 
Takotsubo cardiomyopathy. These results demonstrate that cardiac 
metabolic 
123
I-BMIPP imaging can detect myocardial injury and may be used as a tool 
to diagnose the disease. These typical metabolic SPECT features of the disease can be 
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Legends for illustrations 
 
Fig 1 Left ventricular segmentation. Diagramatic presentation of a circumferential polar 
plot of 17 segment model of left ventricle: 1, basal anterior; 2, basal anteroseptal; 3, 
basal inferoseptal; 4, basal inferior; 5, basal inferolateral; 6, basal anterolateral; 7, mid 
anterior; 8, mid anteroseptal; 9, mid inferoseptal; 10, mid inferior; 11, mid inferolateral; 
12, mid anterolateral; 13, apical anterior; 14, apical septal; 15, apical inferior; 16, apical 
lateral; 17, apex. 
 
 
Fig. 2  Cardiac SPECT image using 
123
I-BMIPP (upper left) and 
99m
Tc-sestamibi 
(MIBI) (upper right) in a 66 year-old male patient with Takotsubo cardiomyopathy. 
Discordant
123
I-BMIPP uptake less than perfusion uptake in the apex is shown. Yellow 
arrow shows decreased uptake of BMIPP in apical area. 
In the acute phase left ventriculography showed apical akinesis and basal normokinesis 
(ED, end-diastole; ES, end-systole). Coronary angiography revealed no stenotic legion 




Fig. 3  Comparison of defect score between apical and non-apical segments in 
Takotsubo cardiomyopathy or AMI. A: The ratio of BMIPP summed defect score of 
non-apical segments to apical segments is shown. B: The ratio of perfusion defect score 
of non-apical segments to the apical segments is shown. Green bar and blue bars are 




Fig. 4   Location of mismatched area between 
123
I-BMIPP and perfusion scan in 
patients with Takotsubo cardiomyopathy (a) and AMI (b) and. Mismatched segments 
were observed in exclusively in apical area in Takotsubo cardiomyopathy. 
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 Table 1  Characteristics of study subjects. 
            Takotsubo cardiomyopathy AMI  p 
   n=16     n=12                  
Age (years)  72±3   67±3  NS 
Male gender  8 (50%)   8 (67%)  NS 
Coronary risk factors 
 Hypertension  7 (44%)   5 (42%)  NS 
 Diabetes mellitus  2 (13%)   3 (19%)  NS 
 Dyslipidemia  1 (6%)   6 (50%)  0.005 
 Current smoking  4 (25%)   5 (42%)  NS 
Peak CPK (IU/L)  261±337   2116±1861 0.0006 
Cardiac Medications  
 Aspirin    1 (6%)   5 (42%)  0.002 
 Beta-blocker  3 (19%)   4 (33%)  NS 
 ACEIs or ARB  4 (25%)   5 (42%)  NS 
 Nitrates   1 (6%)   0 (0%)  NS 
 Any of the above  9 (56%)   7 (58%)  NS      
AMI, acute myocardial infarction; NS, not significant; ACEI, angiotensin converting 
enzyme inhibitor; ARB, angiotensin II receptor blocker; CPK, creatinine phosphokinase   
Table 2    Comparison of 
123
I-BMIPP SPECT defect between Takotsubo 
cardiomyopathy and AMI of left anterior descending coronary artery in 17 segments of 
left ventricle.  
               
   Takotsubo AMI  p 
   Cardiomyopathy                                  
Non-apical area  1.1±2.1  11.7±7.1  <0.0001 
  1, basal anterior  0.1±0.3  1.2±0.3  0.008  
  2, basal anteroseptal 0.1±0.3  1.2±0.3  0.02 
  3, basal inferoseptal  0.1±0.3  1.1±0.3  0.02 
  4, basal inferior  0.0±0.1  0.3±0.2  NS 
  5, basal inferolateral 0.0±0.0  0.0±0.0  NS 
  6, basal anterolateral 0.0±0.04  0.1±0.1  NS  
  7, mid anterior  0.1±0.2  2.8±0.2  <0.0001 
  8, mid anteroseptal  0.1±0.2  2.8±0.2  <0.0001 
  9, mid inferoseptal 0.1±0.2  1.0±0.2  0.002 
  10, mid inferior  0.1±0.1  0.4±0.2  0.2 
  11, mid inferolateral  0.2±0.2  0.3±0.2  NS 
  12, mid anterolateral 0.0±0.2  0.7±0.2  0.04       
Apical area  3.9±2.7  10.8±4.9  <0.0001 
  13, apical anterior    0.4±0.2  3.0±0.2  <0.0001 
  14, apical septal  0.5±0.2  2.8±0.3  <0.0001 
  15, apical inferior  0.6±0.3  0.8±0.3  NS 
  16, apical lateral  0.8±0.3  1.1±0.4  NS 
  17, apex  1.6±0.8  3.0±0.3  0.0002     
BMIPP total defect score    4.8±2.7          22.4±10.7        <0.0001     
 
AMI, acute myocardial infarction; NS, not significant.                        
 
  
 Table 3    Comparison of perfusion defect score between Takotsubo cardiomyopathy 
and AMI of left anterior descending coronary artery in 17 segments of left ventricle.  
               
   Takotsubo AMI  p 
   Cardiomyopathy                                  
Non-apical area  0.9±1.4  4.7±4.5  0.002 
  1, basal anterior  0.0±0.2  0.6±0.2  0.03  
  2, basal anteroseptal 0.07±0.2  0.3±0.2  NS 
  3, basal inferoseptal  0.0±0.06  0.08±0.06 NS 
  4, basal inferior  0.08±0.06 0.0±0.06  NS 
  5, basal inferolateral 0.0±0.0  0.0±0.0  NS 
  6, basal anterolateral 0.0±0.0  0.0±0.0  NS  
  7, mid anterior  0.08±0.2  1.4±0.3  0.0008 
  8, mid anteroseptal  0.15±0.2  1.0±0.2  0.02 
  9, mid inferoseptal 0.08±0.1  0.25±0.1  NS 
  10, mid inferior  0.31±0.1  0.17±0.1  NS 
  11, mid inferolateral  0.08±0.07 0.08±0.08 NS 
  12, mid anterolateral 0.08±0.3  0.75±0.3  NS        
Apical area   1.8±1.8  8.7±5.2  0.0005 
  13, apical anterior    0.23±0.3  2.3±0.3  0.0005 
  14, apical septal  0.23±0.3  1.7±0.3  0.003 
  15, apical inferior  0.23±0.2  0.8±0.2  0.06 
  16, apical lateral  0.23±0.3  1.5±0.3  0.001 
  17, apex  0.77±0.3  2.5±0.3  0.001     
Perfusion total defect score  2.6±2.9          13.3±9.2         <0.0001   
 
AMI, acute myocardial infarction; NS, not significant.                        
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